Abstract
Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Current Chemical Biology
Title: Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Volume: 3 Issue: 2
Author(s): Sylvie Ducki and Elizabeth Bennett
Affiliation:
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Abstract: Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Export Options
About this article
Cite this article as:
Ducki Sylvie and Bennett Elizabeth, Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors, Current Chemical Biology 2009; 3 (2) . https://dx.doi.org/10.2174/2212796810903020146
DOI https://dx.doi.org/10.2174/2212796810903020146 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is There a Role for Antioxidants in the Prevention of Infection-Associated Carcinogenesis and in the Treatment of Infection-Driven Tumors?
Current Topics in Medicinal Chemistry The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry Antimicrobial, In Vitro and In Vivo Antineoplastic Activities, Mechanism of Action, Structural and Thermal Properties of a Small-Novel Pharmaceutical Organometallic Chelate
Mini-Reviews in Medicinal Chemistry Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Current Medicinal Chemistry Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Natural Product Inhibitors of Topoisomerases: Review and Docking Study
Current Protein & Peptide Science Evaluation of Cytotoxic Potentials of Some Isoindole-1, 3-Dione Derivatives on HeLa, C6 and A549 Cancer Cell Lines
Medicinal Chemistry Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Recent Advances on Prediction of Human Papillomaviruses Risk Types
Current Drug Metabolism PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Synthesis and Evaluation of Antioxidant and Cytotoxicity of the N-Mannich Base of Berberine Bearing Benzothiazole Moieties
Anti-Cancer Agents in Medicinal Chemistry Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery